TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company’s fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks.
During the session, Mr. Schuster will review preclinical experience with SynCardia’s next-generation, fully implantable total artificial heart platform, Emperor. The presentation will include bench and acute in vivo data, with emphasis on hemodynamic performance, robustness, physiological responsiveness, and system stability. The session will also feature a personal perspective from Mr. Schuster on how his multidisciplinary background and experience contributed to the development of the Emperor platform, offering insight intended to inspire innovation across the medical device community.
Details of the webinar are below:
Title: The Emperor: A Fully Implantable, Mechanically Driven Next-Generation SynCardia Total Artificial Heart
Date: February 3rd, 2026
Time: 12:00pm ET
Host: DeviceTalks — DeviceTalks Tuesdays Webcast Series
Format: Live virtual webinar
Registration: Click here to register
The webcast will be available for download and streaming on all major platforms, including Apple Podcasts, Spotify, and Google Podcasts and available directly on DeviceTalks Tuesday’s website here.
About DeviceTalks Tuesdays
DeviceTalks Tuesdays iis a weekly webcast series designed to help MedTech professionals stay current and perform at the highest level in service of patients and customers. Organized by the DeviceTalks’ editorial team, the series brings together industry leaders, innovators, and operators for timely discussions and educational sessions tailored to medical technology companies navigating rapid change. Programming focuses on the core pillars of the DeviceTalks platform, including innovation and finance, product development, manufacturing and sourcing, regulatory reimbursement and market development, and emerging tools and technologies shaping the future of the industry. Each session is structured to fit the presenter and topic and may include keynote interviews, panel discussions, interactive presentations, and guided question and answer engagement. DeviceTalks Tuesdays unites MedTech professionals around a shared goal of continuous learning, collaboration, and improvement across the medical device ecosystem.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
[email protected]
Picard Medical, Inc./SynCardia Systems, LLC
[email protected]
General/Media
Brittany Lanza
[email protected]
